Synovial and systemic pharmacokinetics (PK) of triamcinolone acetonide (TA) following intra-articular (IA) injection of an extended-release microsphere-based formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis (OA) V.B. Kraus, P.G. Conaghan, H.A. Aazami, P. Mehra, A.J. Kivitz, J. Lufkin, J. Hauben, J.R. Johnson, N. Bodick Osteoarthritis and Cartilage Volume 26, Issue 1, Pages 34-42 (January 2018) DOI: 10.1016/j.joca.2017.10.003 Copyright © 2017 The Authors Terms and Conditions
Fig. 1 Patient disposition. D/C – discontinuation, LTFU – lost to follow-up. Osteoarthritis and Cartilage 2018 26, 34-42DOI: (10.1016/j.joca.2017.10.003) Copyright © 2017 The Authors Terms and Conditions
Fig. 2 SF TA concentrations (log-linear scale) over time following a single IA injection of FX006 or TAcs. To obtain a reasonable estimate of the GM SF values, a scaler value of 1 was added to each observed concentration value. CI – confidence interval. Osteoarthritis and Cartilage 2018 26, 34-42DOI: (10.1016/j.joca.2017.10.003) Copyright © 2017 The Authors Terms and Conditions
Fig. 3 Blood plasma TA concentrations (log-linear scale) over time following a single IA injection of FX006 or TAcs. Osteoarthritis and Cartilage 2018 26, 34-42DOI: (10.1016/j.joca.2017.10.003) Copyright © 2017 The Authors Terms and Conditions